资产规模保持较快增长。公司 2025 年末资产总额 3.63 万亿元，较年初增长 16.1%，保持较快的扩张速度。其中年末贷款总额 1.73 万亿元，较年初增长 17.4%；存款总额 2.02 万亿元，较年初增长 10.3%，增速相对较低，但活期 存款新增占比 高达 71%。公司 2025 年末归属于普通股股东的净资产 2225 亿 元，较年初增长 6.8%。年末核心一级资本充足率 9.34%，较年初下降 0.50 个百分点。 营收利润增速基本平稳，ROE 继续回落。公司 2025 年实现营业收入 720 亿元， 同比增长 8.0%，增速较前三季度略降 0.3 个百分点；2025 年实现归母净利 润 293 亿元，同比增长 8.1%，增速较前三季度略降 0.3 个百分点。其中，公 司 2025 年实现利息净收入 532 亿元，同比增长 10.8%，增速较前三季度略降 1.0 个百分点；全年实现手续费净收入 61 亿元，同比增长 30.7%，增速较前 三季度提高 1.4 个百分点；全年实现其他非息收入 127 亿元，同比下降 9.0%， 增速与前三季度持平。公司 2025 年实现加权平均净资产收益率 13.1% ...

$$\overline{{{\mathbb{M}}}}\cong\pm\overline{{{\mathbb{M}}}}$$ ($\frac{\pi}{10}$) 宏观与策略 | 晨会纪要 | | --- | | 数据日期:2026-01-20 | 上证综指 | 深证成指沪深 | 300 指数 | 中小板综指 | 创业板综指 | 科创 50 | | --- | --- | --- | --- | --- | --- | --- | | 收盘指数（点） | 4113.64 | 14155.62 | 4718.87 | 15415.84 | 4108.80 | 1482.99 | | 涨跌幅度（%） | 0.00 | -0.96 | -0.32 | -0.75 | -1.66 | -1.58 | | 成交金额（亿元） | 12214.85 | 15561.71 | 6719.60 | 5667.07 | 7026.79 | 977.63 | 宏观月报:宏观经济月报-冬日暖阳新意浓 证券研究报告 | 2026年01月21日 策略专题:活跃资金流入，长线资金流出——1 月第 2 周立体投资策略周 报 总量专题（首席经 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [4] Core Insights - The pharmaceutical sector underperformed the overall market this week, with a 0.68% decline in the biotechnology sector compared to a 0.03% increase in the overall A-share market [1] - The report highlights the successful listing of Rebio Biotech on the Hong Kong Stock Exchange, focusing on the small RNA industry and its potential [2] - Rebio Biotech has established a proprietary delivery platform, RiboGalSTAR, and has entered into commercialization partnerships valued at over $2 billion [2] - The core asset RBD4059, targeting FXI, is currently in clinical phase 2a studies in Sweden, showing promise in treating thrombotic diseases [2][21] Summary by Sections Market Performance - The overall A-share market increased by 0.03%, while the Shanghai Composite Index decreased by 0.57%. The biotechnology sector saw a decline of 0.68% [1][26] - Within the biotechnology sector, chemical pharmaceuticals fell by 2.40%, while medical services rose by 3.29% [1][26] Company Overview - Rebio Biotech focuses on small RNA drug development, with seven products in clinical research, four of which are in phase 2 trials [2][9] - The company has a strong management team with extensive experience in drug development and production [16][18] Financial Projections - The report provides earnings forecasts for key companies, with Rebio Biotech's core asset RBD4059 showing significant potential in the thrombotic disease market [3][21] - The report recommends investment opportunities in the CXO sector and highlights the clinical progress of innovative drugs overseas [2][36] Valuation Metrics - The TTM P/E ratio for the pharmaceutical and biotechnology sector is 38.70x, compared to 22.18x for the overall A-share market [31] - Specific sub-sectors show varying P/E ratios, with chemical pharmaceuticals at 47.60x and medical services at 36.15x [31]

Investment Rating - The report maintains an "Outperform" rating for the industry, indicating expected performance above the market benchmark by over 10% [5][12]. Core Insights - The report highlights significant growth potential in the commercial aerospace sector, driven by SpaceX's ambitious goal of producing 10,000 Starships annually and achieving a launch frequency exceeding once per hour within three years [2][19]. - OpenAI is actively seeking domestic hardware suppliers in the U.S. for its expansion into consumer devices, robotics, and cloud data centers, emphasizing the critical role of hardware in software development [3][19]. Summary by Relevant Sections Commercial Aerospace - The report emphasizes the long-term investment opportunities in commercial aerospace, particularly focusing on key suppliers and the Blue Arrow Aerospace supply chain. Recommended companies include: 1. Rocket components: Huazhu High-Tech, Yingliu Co., Longxi Co. 2. Satellite assembly and testing: Guangdian Measurement, Sutest, Shanghai Huguang. 3. Other relevant companies: Zhongtai Co., Ice Wheel Environment [2][9]. AI Infrastructure - The report expresses optimism regarding the AI infrastructure sector, particularly in gas turbines and liquid cooling technologies. Key recommendations include: 1. Gas turbine components: Yingliu Co., Wanze Co. 2. Gas turbine generator sets: Jerry Co. 3. Other components: Haomai Technology, Liande Co. 4. Liquid cooling systems: Ice Wheel Environment, Hanzhong Precision Machinery, Liande Co. [3][9]. Key Company Earnings Forecasts - The report provides earnings forecasts and investment ratings for several companies, all rated "Outperform": 1. Green's Harmony (688017.SH): Target price of 220.50, market cap of 40.4 billion, EPS of 0.33 for 2024A. 2. Mingzhi Electric (603728.SH): Target price of 73.65, market cap of 30.9 billion, EPS of 0.19 for 2024A. 3. Huichuan Technology (300124.SZ): Target price of 80.85, market cap of 218.9 billion, EPS of 1.60 for 2024A [12][25].

Investment Rating - The report maintains an "Outperform" rating for the agricultural sector [3][5]. Core Insights - The agricultural sector is expected to experience upward price trends, particularly in beef and dairy, while grain prices are stabilizing at historical lows [1][3][5]. - The supply-demand dynamics for corn and soybeans remain loose, with global ending stocks projected to increase, while domestic prices are expected to find strong support at current low levels [1][2][3]. Summary by Relevant Sections Corn - The USDA January supply and demand report forecasts a global corn production increase of 13.05 million tons (approximately +1.02%) to 1.283 billion tons for the 25/26 season, with a corresponding increase in the global ending stocks-to-use ratio by 0.86 percentage points to 22.38% [15][16]. - Domestic corn prices are currently at a historical low, with a slight month-on-month increase of 0.04% and a year-on-year increase of 10.30% [18]. Soybeans - The USDA report indicates a global soybean production increase of 3.14 million tons, with ending stocks projected to rise by 2.04 million tons (approximately +1.67%) to 124 million tons for the 25/26 season [33][34]. - Short-term support for soybean prices is expected from import costs, while long-term trends are anticipated to improve as Brazilian soybeans come to market [35]. Wheat - The USDA report predicts a global wheat production increase of 4.36 million tons (approximately +0.52%) for the 25/26 season, with the ending stocks-to-use ratio increasing by 0.37 percentage points to 33.77% [47][48]. - Domestic wheat prices are expected to stabilize at low levels, with current prices at 2,515 yuan per ton, reflecting a month-on-month decrease of 0.15% [50]. Beef - The USDA forecasts a decrease in U.S. beef production for 2026, with prices expected to rise by approximately 5.1% year-on-year [3][19]. - Domestic beef prices are anticipated to maintain an upward trend due to reduced production capacity and lower imports [3][19]. Dairy - The USDA predicts a slight reduction in U.S. milk ending stocks, with prices expected to remain favorable due to a contraction in domestic dairy cow capacity [3][24]. - The interplay between meat and dairy sectors is expected to drive a recovery in dairy prices [3][24]. Pork - The USDA projects a 2.69% increase in U.S. pork production for 2026, with prices expected to remain stable at high levels [4][28]. - Domestic breeding sow capacity is being managed to support industry profitability [4][29]. Poultry - U.S. chicken production is expected to recover, with prices projected to perform well due to improved consumer demand [6][30]. - Domestic egg supply is anticipated to be ample, with a year-on-year increase in ending stocks by 23.5% [6][33]. Investment Recommendations - Recommended stocks include leading companies in the livestock, pork, poultry, and pet sectors, such as YouRan Agriculture and MuYuan [5][8].

Investment Rating - The report maintains an "Outperform" rating for the agricultural sector [1][3]. Core Insights - The report indicates that the beef prices in the US are expected to maintain an upward trend in 2026, while global corn and soybean ending stocks for the 25/26 season are projected to increase [1][3]. - The agricultural products in the planting chain are currently in a bottom consolidation phase, awaiting upward movement [1][2]. Summary by Relevant Sections Corn - The USDA's January supply and demand report forecasts a global corn production increase of 13.05 million tons (approximately +1.02%) to 1.283 billion tons for the 25/26 season, with a corresponding increase in global ending stocks [15][16]. - The ending stocks-to-use ratio is expected to rise by 0.86 percentage points to 22.38%, with China's ratio increasing by 1.94 percentage points [15][17]. - Domestic corn prices are at historical lows, with a current price of 2318 CNY/ton, reflecting a month-on-month increase of 0.04% and a year-on-year increase of 10.30% [18]. Soybeans - The USDA report predicts a global soybean production increase of 3.14 million tons for the 25/26 season, with ending stocks projected to rise by 2.04 million tons (approximately +1.67%) to 124 million tons [33][34]. - The ending stocks-to-use ratio is expected to increase by 0.39 percentage points to 29.40% [33][34]. - Short-term focus is on South American weather, while long-term trends are expected to improve due to reduced domestic soybean stocks and strong import support [35][37]. Wheat - The USDA's January report indicates a global wheat production increase of 4.36 million tons (approximately +0.52%) for the 25/26 season, with ending stocks projected to rise by 3.38 million tons [47][48]. - The ending stocks-to-use ratio is expected to increase by 0.37 percentage points to 33.77% [47][48]. - Domestic wheat prices are currently at 2515 CNY/ton, reflecting a month-on-month decrease of 0.15% [50][52]. Beef - The USDA forecasts a decrease in US beef production for 2026, with an expected overall price increase of approximately 5.1% [3][19]. - The report anticipates that domestic beef prices will maintain a bottoming upward trend due to reduced production capacity and import constraints [3][22]. Dairy - The report notes a slight decrease in US milk ending stocks for 2026, with expectations for domestic raw milk prices to begin an upward trend due to reduced production capacity and import reductions [3][24][26]. Pork - The USDA predicts a 2.69% increase in US pork production for 2026, with overall prices expected to remain high [4][28]. - Domestic breeding sow capacity is being steadily controlled, which is expected to support industry profitability [4][29]. Poultry - The report indicates that US chicken supply is expected to recover, with a slight increase in production and consumption [6][30]. - Domestic egg supply is projected to remain ample, with a year-on-year increase in ending stocks by 23.5% [6][33][34]. Investment Recommendations - The report recommends investing in leading companies in the livestock, pork, poultry, and pet sectors, including YouRan Agriculture, Modern Agriculture, and MuYuan Co., among others [6][8].

- The report discusses the market performance of various indices, including the Shanghai Composite Index, which performed relatively well, and the CSI 300 Value Index, which also showed positive performance[2][6] - The report highlights the performance of different industry indices, with the petroleum and petrochemical, building materials, real estate, construction, and transportation industries performing well, while the defense, communications, computer, comprehensive finance, and electrical industries performed poorly[7] - The report provides data on market sentiment, including the number of stocks that hit their daily limit up or down, and the performance of these stocks the following day[13][14] - The report includes information on market capital flows, such as the balance of margin financing and securities lending, and the proportion of these balances relative to the total market capitalization[19][22] - The report discusses the premium and discount rates of ETFs, highlighting the ETFs with the highest premiums and discounts on a specific day[23][25] - The report provides data on block trading, including the average daily transaction amount and discount rate over the past six months[26][28] - The report includes information on the annualized discount rates of the main contracts of stock index futures for various indices, such as the Shanghai 50, CSI 300, CSI 500, and CSI 1000[28][30] - The report highlights the stocks that received the most institutional attention over the past week, with specific stocks being mentioned[30][32] - The report provides data on the top ten stocks with the highest net inflows and outflows from institutional seats and the Shanghai-Hong Kong Stock Connect[36][37][38][40]

Investment Rating - The report maintains an "Outperform" rating for the industry, indicating expected performance above the market benchmark by more than 10% [5][12]. Core Insights - The commercial space sector is expected to experience significant growth, driven by SpaceX's ambitious goal of producing 10,000 Starships annually and achieving a launch frequency exceeding once per hour within three years [2][19]. - OpenAI is actively seeking domestic hardware suppliers in the U.S. for its expansion into consumer devices, robotics, and cloud data centers, highlighting the critical role of hardware in supporting software development [3][19]. Summary by Relevant Sections Commercial Space - The report emphasizes the long-term investment opportunities in the commercial space sector, particularly focusing on key suppliers and the Blue Arrow Aerospace industry chain. Recommended companies include: 1. Rocket components: Huazhu High-Tech, Yingliu Co., Longxi Co. 2. Satellite assembly and testing: Guangdian Measurement, Sushitest, Shanghai Huguang. 3. Other relevant companies: Zhongtai Co., Icewheel Environment [2][9]. AI Infrastructure - The report highlights the importance of hardware support for AI development, noting that China's hardware supply chain is more complete and cost-effective. Key areas of focus include: 1. Gas turbines as primary and backup power sources for overseas data centers, with companies like Yingliu Co. and Wanze Co. recommended. 2. Liquid cooling solutions for data centers, with a shift from air cooling to liquid cooling being a significant trend. Key companies include Icewheel Environment, Hanzhong Precision, and Linde Co. [3][9]. Key Company Earnings Forecasts - The report provides earnings forecasts and investment ratings for several companies, all rated as "Outperform": 1. Green's Harmony (688017.SH): Target price of 220.50, market cap of 40.4 billion, EPS of 0.33 for 2024A. 2. Mingzhi Electric (603728.SH): Target price of 73.65, market cap of 30.9 billion, EPS of 0.19 for 2024A. 3. Huichuan Technology (300124.SZ): Target price of 80.85, market cap of 218.9 billion, EPS of 1.60 for 2024A [12][25].

Investment Rating - The report maintains an "Outperform" rating for the livestock industry, indicating a positive outlook for the sector [4]. Core Insights - The implementation of import beef restrictions through a "quota + tariff" system is expected to reduce the volume of imported beef while increasing prices, signaling strong protection for the domestic beef industry [1][12]. - Global beef prices are entering an upward cycle due to reduced supply in major producing regions and strong demand in consuming areas, with a projected price increase of nearly 60% from the bottom by the end of 2025 [2][52]. - Domestic beef supply and demand dynamics indicate a price increase trend that may continue until 2028, driven by a significant reduction in cow numbers and subsequent tightening of beef supply [3][19]. Summary by Sections Import Beef Policy Analysis - The Chinese government has implemented protective measures for the domestic beef industry, with a quota and additional tariffs on imported beef starting January 1, 2026, for a duration of three years [1][12]. - The expected import volume for 2026 is projected to be approximately 2.34 million tons, a reduction of nearly 20% compared to 2024 [1][15][42]. Overseas Beef Price Cycle Outlook - Global beef prices are expected to maintain an upward trend due to supply reductions in major producing areas and strong demand in consuming regions [2][44]. - The FAO reports that global beef prices have increased by nearly 60% from their lowest point as of December 2025 [2][52]. Domestic Beef Supply and Demand Analysis - The domestic beef industry is experiencing a turning point, with a significant increase in prices anticipated until 2028 due to a reduction in cow numbers and a tightening supply [3][19]. - The report highlights that the beef production cycle has a lag effect, with the impact of cow culling expected to be felt from early 2026 through 2028, leading to a widening supply gap [3][20].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [4] Core Insights - The pharmaceutical sector underperformed the overall market, with a TTM P/E ratio of 38.70x, which is at the 84.85th percentile of the past five years [1][31] - The report highlights the recent IPO of RiboBio, a leading company in the small RNA drug development sector, which has established a proprietary delivery platform, RiboGalSTAR, focusing on cardiovascular, metabolic, renal, and liver diseases [2][9] - RiboBio has seven products in clinical research, with four advancing to Phase II trials, demonstrating the effectiveness and safety of its delivery system [2][17] Summary by Sections Market Performance - The overall A-share market increased by 0.03%, while the biopharmaceutical sector declined by 0.68%, with chemical pharmaceuticals dropping by 2.40% [1][26] - The report notes significant individual stock movements, with some companies experiencing substantial gains and others facing steep declines [26][30] Company Focus: RiboBio - RiboBio has formed strategic partnerships with Boehringer Ingelheim and Qilu Pharmaceutical, with a total transaction value exceeding $2 billion, validating the platform's value [2][17] - The core asset, RBD4059, is in Phase IIa trials in Sweden for treating thrombotic diseases, showing promising results in reducing thrombus formation without increasing bleeding risk [2][21] - RBD4059's clinical data indicates a significant reduction in FXI activity, with a maximum percentage change of 91.6% at the highest dosage [22] Investment Recommendations - The report suggests focusing on investment opportunities in the CXO sector and the clinical progress of innovative drugs overseas [2] - Specific companies recommended for investment include Mindray Medical, WuXi AppTec, and Aier Eye Hospital, all rated as "Outperform" [3][36]